Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28771898 | 0.98 | PARP1 (0.49) | PARP1PIN1GLAALDH1A1ADORA2A | |
| Hydrochloric Acid SCHEMBL27755480 | 0.98 | PARP1 (0.49) | PARP1PIN1GLAALDH1A1ADORA2A | |
| Hydrochloric Acid SCHEMBL27755490 | 0.97 | PARP1 (0.47) | PARP1PIN1GLAALDH1A1ADORA2A | |
| SCHEMBL28007491 | 0.85 | PIN1 (0.47) | PARP1PIN1ALDH1A1ADORA2A | |
| SCHEMBL984268 | 0.84 | PIN1 (0.52) | PIN1ALDH1A1 | |
| SCHEMBL15897691 | 0.82 | PIN1 (0.45) | PIN1GLAALDH1A1 | |
| Hydrochloric Acid SCHEMBL27755478 | 0.82 | PIN1 (0.51) | PIN1ALDH1A1 | |
| SCHEMBL2009467 | 0.82 | PIN1 (0.42) | PARP1PIN1ALDH1A1ADORA2A | |
| Hydrochloric Acid SCHEMBL27928599 | 0.82 | PIN1 (0.51) | PIN1ALDH1A1 | |
| SCHEMBL27755564 | 0.82 | PIN1 (0.51) | PIN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| US-20090270377-A1 | COMBINATION CANCER CHEMOTHERAPY | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-29 | — | — | US | claimed |
| CN-101160307-A | Benzoxazole carboxamides for the treatment of CINV and IBS-D | AMR TECHNOLOGY INC (US) | 2008-04-09 | — | — | CN | claimed |
| WO-2007137000-A2 | COMBINATION CANCER CHEMOTHERAPY | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-11-29 | — | — | WO | claimed |
| EP-0897915-B1 | Quinazolinone compounds as chemotherapeutic agents | UNIV NEWCASTLE VENTURES LTD (GB) | 2003-01-22 | — | — | EP | claimed |
| CN-1081624-C | Benzamide analogs, useful as PARP (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | NEWCASTLE UNIV VENTURE INVEST (GB) | 2002-03-27 | — | — | CN | claimed |
| EP-0879820-B1 | Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 2001-12-12 | — | — | EP | claimed |
| US-6316455-B1 | Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-11-13 | — | — | US | claimed |
| EP-0897915-A1 | QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-02-24 | — | — | EP | claimed |
| EP-0879820-A1 | Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-11-25 | — | — | EP | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| CN-1143358-A | Benzamide analogs, useful as parp (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 1997-02-19 | — | — | CN | claimed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH Zürich (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-4282490-B1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH ZUERICH (CH) | 2025-11-12 | — | — | EP | disclosed |
| CN-118302433-A | Fibronectin binding peptides for diagnosis and treatment of tumors or fibrosis | 苏黎世联邦理工学院 | 2024-07-05 | — | — | CN | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| CN-1094400-A | Heterogeneous ring compound | ZENECA LTD (GB) | 1994-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | FN1, ASNS, FNIP1 | PARP1 2788/4885PIN1 1697/4885GLA 1529/4885 |
| US-20090270377-A1 | COMBINATION CANCER CHEMOTHERAPY | NCL, NSUN3, NOP58 | PARP1 118/4885PIN1 2025/4885GLA 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.